Zealand Pharma A/S (ZEAL.CO)
| Previous close | 926.00 |
| Open | 930.00 |
| Bid | 887.00 x 0 |
| Ask | 889.00 x 0 |
| Day's range | 885.00 - 951.00 |
| 52-week range | 212.20 - 972.00 |
| Volume | |
| Avg. volume | 339,758 |
| Market cap | 62.807B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.36 |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 978.29 |
ZacksHere's What Could Help Zealand Pharma AS (ZLDPF) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
GlobeNewswireZealand Pharma major shareholder announcement: Van Herk Investments
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 28 June 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As from 28 Ju
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar
